apomorphine and metoclopramide: what the product label says
Read the product-label passage naming metoclopramide, with the source version, formulation and limitations.
The product label for apomorphine names ondansetron in its drug-interaction information. The complete selected section is reproduced below so that qualifications stay with the finding.
ONAPGO โ INJECTION, SOLUTION โ SUBCUTANEOUS
Labeled active ingredients: APOMORPHINE HYDROCHLORIDE; APOMORPHINE. Routes: SUBCUTANEOUS. Dosage forms: INJECTION, SOLUTION.
Section: 7.1 5HT 3 Antagonists
Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of ONAPGO with 5HT 3 antagonists, including antiemetics (e.g., ondansetron, granisetron, palonosetron) and alosetron, is contraindicated [see Warnings and Precautions (5.4) ].
Read the full product label on DailyMed. Label version 21, dated 2026-10-05.
This passage applies to the labeled product and circumstances it describes. It must not be generalized to other routes or formulations. It does not independently validate CDIโs severity category, establish safety for an individual, or replace the full label. The stored interaction description and classification have not been changed by this article.
Automatic checks matched drug identities, retrieved and preserved the label, and checked the full quoted section with AI assistance on 2026-11-06. The public explanation uses a fixed template; model-written medical advice is not published. Independent clinical review has not been recorded.
Ask your pharmacist or prescriber whether the cited products, routes and circumstances apply to your medicines before changing treatment.
CDI checks every pair across up to 20 drugs โ backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Read the product-label passage naming metoclopramide, with the source version, formulation and limitations.
Read the product-label passage naming phenytoin, with the source version, formulation and limitations.
Read the product-label passage naming carbamazepine, with the source version, formulation and limitations.